3-(2-Methylquinolin-4-ylamino)-5-trifluoromethylphenol | 1147011-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-(2-Methylquinolin-4-ylamino)-5-trifluoromethylphenol
• 英文别名: 3-[(2-Methylquinolin-4-yl)amino]-5-(trifluoromethyl)phenol
• CAS: 1147011-66-2
• 化学式: C₁₇H₁₃F₃N₂O
• 分子量: 318.298
• InChiKey: UIALEEPJRCIJHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
  申请人：Wu Chengde

  公开号：US20050054850A1

  公开（公告）日：2005-03-10

  The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.

  本发明涉及尿苷II受体拮抗剂，含有它们的药物组合物以及它们的用途。
• US7320989B2
  申请人：——

  公开号：US7320989B2

  公开（公告）日：2008-01-22
• [EN] QUINOLINE UROTENSIN-II RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE L'UROTENSINE II DE LA QUINOLÉINE
  申请人：ENCYSIVE PHARMACEUTICALS INC

  公开号：WO2009053895A2

  公开（公告）日：2009-04-30

  Provided are compounds that are modulators of urotensin-II receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of urotensin-II receptor activity.
• [EN] MODULATORS OF UROTENSIN RECEPTOR AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DU RÉCEPTEUR DE L'UROTENSINE ET LEURS MÉTHODES D'UTILISATION
  申请人：ENCYSIVE PHARMACEUTICALS INC

  公开号：WO2009063364A2

  公开（公告）日：2009-05-22

  Provided are compounds that are modulators of urotensin-II receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of urotensin-II receptor activity wherein the disease is a cardiovascular disorder, atherosclerosis, renal failure, nephrotoxicity and diarrhea caused by antineoplastic agents, post-myocardial infarction, pulmonary hypertension, diabetes or a CNS related disease.